{"title":"Phylogenetic distribution of DNA topoisomerase VI and its distinction from SPO11.","authors":"Adam M B Allen, Anthony Maxwell","doi":"10.1093/nargab/lqae085","DOIUrl":null,"url":null,"abstract":"<p><p>DNA topoisomerases (topos) are major targets for antimicrobial and chemotherapeutic drugs due to their fundamental roles in regulating DNA topology. Type II topos are essential for chromosome segregation and relaxing positive DNA supercoils, and are exemplified by topo II in eukaryotes, topo IV and DNA gyrase in bacteria, and topo VI in archaea. Topo VI occurs ubiquitously in plants and sporadically in bacteria, algae, and other protists and is highly homologous to Spo11, which initiates eukaryotic homologous recombination. This homology makes the two complexes difficult to distinguish by sequence and leads to discrepancies such as the identity of the putative topo VI in malarial <i>Plasmodium</i> species. A lack of understanding of the role and distribution of topo VI outside of archaea hampers its pursuit as a potential drug target, and the present study addresses this with an up-to-date and extensive phylogenetic analysis. We show that the A and B subunits of topo VI and Spo11 can be distinguished using phylogenetics and structural modelling, and that topo VI is not present in <i>Plasmodium</i> nor other members of the phylum Apicomplexa. These findings provide insights into the evolutionary relationships between topo VI and Spo11, and their adoption alongside other type II topos.</p>","PeriodicalId":33994,"journal":{"name":"NAR Genomics and Bioinformatics","volume":"6 3","pages":"lqae085"},"PeriodicalIF":4.0000,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11302465/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NAR Genomics and Bioinformatics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/nargab/lqae085","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0
Abstract
DNA topoisomerases (topos) are major targets for antimicrobial and chemotherapeutic drugs due to their fundamental roles in regulating DNA topology. Type II topos are essential for chromosome segregation and relaxing positive DNA supercoils, and are exemplified by topo II in eukaryotes, topo IV and DNA gyrase in bacteria, and topo VI in archaea. Topo VI occurs ubiquitously in plants and sporadically in bacteria, algae, and other protists and is highly homologous to Spo11, which initiates eukaryotic homologous recombination. This homology makes the two complexes difficult to distinguish by sequence and leads to discrepancies such as the identity of the putative topo VI in malarial Plasmodium species. A lack of understanding of the role and distribution of topo VI outside of archaea hampers its pursuit as a potential drug target, and the present study addresses this with an up-to-date and extensive phylogenetic analysis. We show that the A and B subunits of topo VI and Spo11 can be distinguished using phylogenetics and structural modelling, and that topo VI is not present in Plasmodium nor other members of the phylum Apicomplexa. These findings provide insights into the evolutionary relationships between topo VI and Spo11, and their adoption alongside other type II topos.
DNA 拓扑异构酶(拓扑酶)是抗菌药和化疗药的主要靶点,因为它们在调节 DNA 拓扑结构方面发挥着重要作用。真核生物中的拓扑 II、细菌中的拓扑 IV 和 DNA 回旋酶以及古细菌中的拓扑 VI 是拓扑 II 型拓扑酶的典型代表。Topo VI 在植物中普遍存在,在细菌、藻类和其他原生生物中也时有发生,它与启动真核生物同源重组的 Spo11 高度同源。这种同源性使得这两种复合体很难通过序列加以区分,并导致了一些差异,例如恶性疟原虫中的推定拓扑 VI 的身份。对拓扑 VI 在古细菌之外的作用和分布缺乏了解阻碍了将其作为潜在药物靶点的研究,本研究通过最新和广泛的系统发育分析解决了这一问题。我们的研究表明,通过系统发生学和结构建模,可以区分拓扑 VI 和 Spo11 的 A 和 B 亚基,而且拓扑 VI 不存在于疟原虫和棘球藻门的其他成员中。这些发现有助于深入了解拓扑 VI 和 Spo11 之间的进化关系,以及它们与其他 II 型拓扑的并存情况。